85 results on '"Edan, C"'
Search Results
2. Treatment of childhood Hodgkin lymphoma in sub-Saharan Africa: A report from the French-African Paediatric Oncology Group (GFAOP)
- Author
-
Traore, F, Diagne Akonde, F B, Togo, B, Moreira, C, Rakotomahefa, N M, Pondy, A, Bouda, C, Harif, M, Eshun, F, and Edan, C
- Abstract
BACKGROUND. Childhood Hodgkin lymphoma (HL) is typically treated by chemo- and radiotherapy, depending on the stage of the disease. Studies on the treatment of HL by chemotherapy alone have shown encouraging results.OBJECTIVE. To evaluate the feasibility, epidemiological and therapeutic aspects of paediatric HL treated with only COPP/ABV hybrid chemotherapy (cyclophosphamide, vincristine, procarbazine, prednisone, adriamycin, bleomycin and vinblastine).METHODS. This was a prospective multicentre study on the management of HL in paediatric oncology centres of the French-African Paediatric Oncology Group in sub-Saharan Africa, from 1 October 2006 to 30 November 2012. To be included in the study, patients had to be younger than 18 years at diagnosis, with histologically proven HL.RESULTS. A total of 106 patients were included, with a median age of 10 years (range: 2-18 years). The sex ratio was 3.1, with a preponderance of male patients (male: n=80; female: n=26). The largest number of patients were in stage IIIB (n=47), IIB (n=18) and IVB (n=15); other stages were represented to a lesser extent. More than 80% of patients had an unfavourable initial prognosis. On biopsy, the nodular sclerosis subtype was observed in 36% of patients (n=38), followed by mixed cellularity (n=21; 20%) and the lymphocyte-rich subtype (n=17; 16%). Eighteen patients relapsed. The overall survival rate of treated patients was 82% at a median follow-up of 30 months.CONCLUSION. The treatment of childhood HL in sub-Saharan Africa is challenging. The use of a hybrid chemotherapy protocol alone can be effective at improving patient survival.
- Published
- 2020
3. Place des réseaux et des équipes mobiles de soins palliatifs en néonatologie
- Author
-
Edan, C., primary and Suc, A., additional
- Published
- 2011
- Full Text
- View/download PDF
4. Treatment of childhood Hodgkin lymphoma in sub-Saharan Africa: A report from the French-African Paediatric Oncology Group (GFAOP)
- Author
-
Diagne Akonde, F B, primary, Togo, B, additional, Moreira, C, additional, Rakotomahefa, N M, additional, Pondy, A, additional, Bouda, C, additional, Harif, M, additional, Eshun, F ESHUN, additional, and Edan, C EDAN, additional
- Published
- 2020
- Full Text
- View/download PDF
5. Standard-Risk Medulloblastoma Treated by Adjuvant Chemotherapy Followed by Reduced-Dose Craniospinal Radiation Therapy: A French Society of Pediatric Oncology Study
- Author
-
Oyharcabal-Bourden, V, Kalifa, C, Gentet, J C., Frappaz, D, Edan, C, Chastagner, P, Sariban, E, Pagnier, A, Babin, A, Pichon, F, Neuenschwander, S, Vinchon, M, Bours, D, Mosseri, V, Le Gales, C, Ruchoux, M, Carrie, C, and Doz, F
- Published
- 2005
- Full Text
- View/download PDF
6. Long-Term Renal and Hearing Toxicity of Carboplatin in Infants Treated for Localized and Unresectable Neuroblastoma: Results of the SFOP NBL90 Study
- Author
-
Bergeron, C., Dubourg, L., Chastagner, P., Mechinaud, F., Plouvier, E., Desfachelles, A. S., Dusol, F., Pautard, B., Edan, C., Plantaz, D., Froehlich, P., and Rubie, H.
- Published
- 2005
- Full Text
- View/download PDF
7. Lymphocyte-Predominant Hodgkinʼs Lymphoma in Children: Therapeutic Abstention After Initial Lymph Node Resection—A Study of the French Society of Pediatric Oncology
- Author
-
Pellegrino, B., Terrier-Lacombe, M. J., Oberlin, O., Leblanc, T., Perel, Y., Bertrand, Y., Beard, C., Edan, C., Schmitt, C., Plantaz, D., Pacquement, H., Vannier, J. P., Lambilliote, C., Couillault, G., Babin-Boilletot, A., Thuret, I., Demeocq, F., Leverger, G., Delsol, G., and Landman-Parker, J.
- Published
- 2003
8. Treatment of childhood Hodgkin lymphoma in sub-Saharan Africa: A report from the French-African Paediatric Oncology Group (GFAOP).
- Author
-
Traore, F., Akonde, F. B. Diagne, Togo, B., Moreira, C., Rakotomahefa, N. M., Pondy, A., Bouda, C., Harif, M., Eshun, F., and Edan, C.
- Subjects
HODGKIN'S disease ,SURVIVAL analysis (Biometry) ,DISEASE relapse ,ONCOLOGY ,DOXORUBICIN - Abstract
Background. Childhood Hodgkin lymphoma (HL) is typically treated by chemo- and radiotherapy, depending on the stage of the disease. Studies on the treatment of HL by chemotherapy alone have shown encouraging results. Objective. To evaluate the feasibility, epidemiological and therapeutic aspects of paediatric HL treated with only COPP/ABV hybrid chemotherapy (cyclophosphamide, vincristine, procarbazine, prednisone, adriamycin, bleomycin and vinblastine). Methods. This was a prospective multicentre study on the management of HL in paediatric oncology centres of the French-African Paediatric Oncology Group in sub-Saharan Africa, from 1 October 2006 to 30 November 2012. To be included in the study, patients had to be younger than 18 years at diagnosis, with histologically proven HL. Results. A total of 106 patients were included, with a median age of 10 years (range: 2 - 18 years). The sex ratio was 3.1, with a preponderance of male patients (male: n=80; female: n=26). The largest number of patients were in stage IIIB (n=47), IIB (n=18) and IVB (n=15); other stages were represented to a lesser extent. More than 80% of patients had an unfavourable initial prognosis. On biopsy, the nodular sclerosis subtype was observed in 36% of patients (n=38), followed by mixed cellularity (n=21; 20%) and the lymphocyte-rich subtype (n=17; 16%). Eighteen patients relapsed. The overall survival rate of treated patients was 82% at a median follow-up of 30 months. Conclusion. The treatment of childhood HL in sub-Saharan Africa is challenging. The use of a hybrid chemotherapy protocol alone can be effective at improving patient survival. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Les soins palliatifs pédiatriques en 2014 : savoirs et incertitude
- Author
-
Edan, C.
- Published
- 2024
- Full Text
- View/download PDF
10. CO-51 – Usage d'une FICHE SAMU Pallia en Soins Palliatifs Pédiatriques
- Author
-
Letourneur, I., primary, Farges, C., additional, Lalou, M., additional, Calmanti, S., additional, and Edan, C., additional
- Published
- 2015
- Full Text
- View/download PDF
11. Les soins palliatifs pédiatriques en 2014 : savoirs et incertitude
- Author
-
Edan, C., primary
- Published
- 2014
- Full Text
- View/download PDF
12. Cross-cultural adaptation of a health status classification system in children with cancer. First results of the French adaptation of the Health Utilities Index Marks 2 and 3
- Author
-
Le Galès C, Nathalie Costet, Jc, Gentet, Kalifa C, Frappaz D, Edan C, Sariban E, Plantaz D, and Doz F
- Subjects
Adult ,Cross-Cultural Comparison ,Adolescent ,Child, Preschool ,Health Status ,Neoplasms ,Surveys and Questionnaires ,Quality of Life ,Humans ,France ,Cranial Irradiation ,Child - Abstract
Our objective was to adapt and validate the Health Utilities Index Mark 2 (HUI 2) and HUI 3 health status classification systems self-report questionnaire in a population of children with cancer, a group of 42 children already included in a multi-centre database designed by the Group on Brain Tumors in Children of the French Society for Pediatric Oncology. Children were recruited during a routine consultation. Most of them had completed treatment. The version of the questionnaire for French adults was adapted linguistically for children. Open-ended queries by children about the comprehensiveness of the questions and very low non-response rates showed a good acceptability of the questionnaire. The main psychometric properties of the HUI 2 and HUI 3 classification systems were assessed in 3 groups of raters (child, parent, physician): construct validity was tested against the rating of the child's health state on a Likert scale and through comparison with clinical data, and internal consistency was determined through multi-trait analysis. Weighted and unweighted kappa values were used to measure the inter-rater agreement between the child's, parent's and physician's assessment of the child's health state. The convergent validity was satisfactory, with better results when the physician's assessment was used. The most affected attributes were the expected ones (i.e., cognition, pain and emotion). Disagreement was observed between the 3 raters, more often in the same direction: taking the child's assessment as the reference, the parents tended to under-estimate the health status while physicians tended to over-estimate it.
- Published
- 2000
13. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study.
- Author
-
Verlooy, J, Mosseri, V, Bracard, S, Tubiana, A Lellouch, Kalifa, C, Pichon, F, Frappaz, D, Chastagner, P, Pagnier, A, Bertozzi, A-I, Gentet, J C, Sariban, Eric, Rialland, X, Edan, C, Bours, D, Zerah, M, Le Gales, C, Alapetite, C, Doz, F, Verlooy, J, Mosseri, V, Bracard, S, Tubiana, A Lellouch, Kalifa, C, Pichon, F, Frappaz, D, Chastagner, P, Pagnier, A, Bertozzi, A-I, Gentet, J C, Sariban, Eric, Rialland, X, Edan, C, Bours, D, Zerah, M, Le Gales, C, Alapetite, C, and Doz, F
- Abstract
AIM: Improvement of EFS of children older than 3 years with high risk medulloblastoma. METHODS: Between 1993 and 1999, 115 patients (3-18 years, mean 8 years) with high risk medulloblastoma were included. After surgery treatment consisted of chemotherapy ('8in1' and etoposide/carboplatin) before and after craniospinal radiotherapy. RESULTS: Patients were staged using Chang-criteria (PF residue only, M1 and M2/M3) by local investigator as well as by central review panel (82.4% concordance). Chemotherapy was well tolerated without major delays in radiotherapy. With a mean follow up of 81 months (9-119), 5-year EFS was 49.8% and OS 60.1%. In detail according to subgroups EFS was 68.8% for PF residue only, 58.8% for M1 disease and 43.1% for M2/M3. CONCLUSION: M1 patients are legitimate high risk patients. Survival rates are still very low for high risk medulloblastoma patients and future trials should therefore focus on more intensive (chemotherapy/radiotherapy) treatment., Journal Article, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2006
14. ATYPICAL TERATOID RHABDOID TUMOR (ATRT)
- Author
-
Hasselblatt, M., primary, Kordes, U., additional, Wolff, J., additional, Jeibmann, A., additional, Fruhwald, M., additional, Paulus, W., additional, Hasselblatt, M., additional, Isken, S., additional, Siebert, R., additional, Schneppenheim, R., additional, Benesch, M., additional, Fleischhack, G., additional, Gruhn, B., additional, Schlegel, P.-G., additional, Witt, O., additional, Holter, W., additional, Reiter, A., additional, Urban, C., additional, Fruhwald, M. C., additional, Lafay-Cousin, L., additional, Huang, A., additional, Hawkins, C., additional, Fryer, C., additional, Bouffet, E., additional, Kruchko, C., additional, Propp, J., additional, McCarthy, B., additional, Dolecek, T., additional, Kerl, K., additional, Unland, R., additional, Jurgens, H., additional, Kieran, M. W., additional, Roberts, C. W. M., additional, Biegel, J. A., additional, MacConaill, L. E., additional, Rich, B. E., additional, Ligon, K. L., additional, Chi, S., additional, Kondo, A., additional, Shimoji, K., additional, Ogino, I., additional, Junya, F., additional, Sakaguchi, S., additional, Miyajima, M., additional, Arai, H., additional, Alimova, I., additional, Knipstein, J., additional, Harris, P., additional, Venkataraman, S., additional, Marquez, V., additional, Birks, D., additional, Foreman, N., additional, Vibhakar, R., additional, Bartelheim, K., additional, Warmuth-Metz, M., additional, Kortmann, R.-D., additional, Gerss, J., additional, Rizzo, D., additional, Freneaux, P., additional, Brisse, H., additional, Parfait, B., additional, Doz, F., additional, Dufour, C., additional, Stephan, J.-L., additional, Edan, C., additional, Ranchere-Vince, D., additional, Peuchmaur, M., additional, Delattre, O., additional, Bourdeaut, F., additional, Soh, S. Y., additional, Chan, M. Y., additional, Seow, W. T., additional, Chang, K., additional, Ng, W. H., additional, Tan, A. M., additional, Yamasaki, K., additional, Tanaka, C., additional, Okada, K., additional, Fujisaki, H., additional, Osugi, Y., additional, Hara, J., additional, Matsusaka, Y., additional, Sakamoto, H., additional, Inoue, T., additional, Batchelder, P., additional, DeMasters, B. K., additional, Handler, M., additional, Sumerauer, D., additional, Vasovcak, P., additional, Puchmajerova, A., additional, Zapotocky, M., additional, Vicha, A., additional, Kyncl, M., additional, Zamecnik, J., additional, Sedlacek, Z., additional, Kodet, R., additional, Geludkova, O., additional, Kumirova, E., additional, Korshunov, A., additional, Kushel, Y., additional, Melikyan, A., additional, Shishkina, L., additional, Ryzhova, M., additional, Ozerova, V., additional, Gorbatyh, S., additional, Popov, V., additional, Pavlova, E., additional, Scherbenko, O., additional, Borodina, I., additional, Donson, A., additional, Dunham, C., additional, Algar, E., additional, Popovski, D., additional, Muscat, A., additional, Ashley, D., additional, Modena, P., additional, Sardi, I., additional, Brenca, M., additional, Giunti, L., additional, Maestro, R., additional, Buccoliero, A. M., additional, Pollo, B., additional, Genitori, L., additional, Giangaspero, F., additional, Massimino, M., additional, Amani, V., additional, Griesinger, A., additional, Bemis, L., additional, Schittone, S., additional, Puccetti, D., additional, Wargowski, D., additional, Messiaen, L., additional, Patel, N., additional, Salamat, S., additional, Rusinak, D., additional, Iskandar, B., additional, Lun, X., additional, Jayanthan, A., additional, Forsyth, P., additional, and Narendran, A., additional
- Published
- 2012
- Full Text
- View/download PDF
15. Gliomatose cérébrale envahissant la substance grise chez l’enfant : une entité distincte ? Étude multicentrique de 14 cas
- Author
-
Riffaud, L., primary, Chappe, C., additional, Treguier, C., additional, Carsin-Nicol, B., additional, and Edan, C., additional
- Published
- 2011
- Full Text
- View/download PDF
16. Maladie de Hodgkin et auto-immunité chez l’enfant : à propos de 11 observations
- Author
-
Jarrassé, C., primary, Pagnier, A., additional, Edan, C., additional, Landman-Parker, J., additional, Mazingue, F., additional, Mansuy, L., additional, Bertrand, Y., additional, Paillard, C., additional, Pellier, I., additional, Margueritte, G., additional, and Plantaz, D., additional
- Published
- 2011
- Full Text
- View/download PDF
17. CL107 - La scolarité des enfants survivants au cancer : attention aux adolescents!
- Author
-
Bonneau, J., primary, Lebreton, J., additional, Taque, S., additional, Chappe, C., additional, Bayart, S., additional, Edan, C., additional, Le Gall, E., additional, and Gandemer, V., additional
- Published
- 2010
- Full Text
- View/download PDF
18. CL099 - Évaluation des recommandations MDH03 pour le traitement des lymphomes de Hodgkin de l’enfant
- Author
-
Seror, E., primary, Leblanc, T., additional, Lambilliotte, A., additional, Pacquement, H., additional, Donadieu, J., additional, Schell, M., additional, Robert, A., additional, André, N., additional, Gorde-Grosjean, S., additional, Schmitt, C., additional, Edan, C., additional, Perel, Y., additional, Carrie, C., additional, Oberlin, O., additional, and Landman-Parker, J., additional
- Published
- 2010
- Full Text
- View/download PDF
19. Two Congenital Cases of Pigmented Epithelioid Melanocytoma Studied by Fluorescent in situ Hybridization for Melanocytic Tumors: Case Reports and Review of These Recent Topics
- Author
-
Battistella, M., primary, Prochazkova-Carlotti, M., additional, Berrebi, D., additional, Bennaceur, S., additional, Edan, C., additional, Riffaud, L., additional, Rütten, A., additional, and Fraitag, S., additional
- Published
- 2010
- Full Text
- View/download PDF
20. SFCE-P28 – Hématologie, immunologie – Maladie de Hodgkin et auto-immunité chez l’enfant : à propos de dix observations
- Author
-
Jarrassé, C., primary, Pagnier, A., additional, Edan, C., additional, Mazingue, F., additional, Landman-Parker, J., additional, Bertrand, Y., additional, Mansuy, L., additional, Demeocq, F., additional, Pellier, I., additional, and Plantaz, D., additional
- Published
- 2008
- Full Text
- View/download PDF
21. Cross-cultural adaptation of a health status classification system in children with cancer. First results of the French adaptation of the Health Utilities Index Marks 2 and 3.
- Author
-
Le Gales, C, Costet, N, Gentet, J C, Kalifa, C, Frappaz, D, Edan, C, Sariban, Eric, Plantaz, D, Doz, F, Le Gales, C, Costet, N, Gentet, J C, Kalifa, C, Frappaz, D, Edan, C, Sariban, Eric, Plantaz, D, and Doz, F
- Abstract
Our objective was to adapt and validate the Health Utilities Index Mark 2 (HUI 2) and HUI 3 health status classification systems self-report questionnaire in a population of children with cancer, a group of 42 children already included in a multi-centre database designed by the Group on Brain Tumors in Children of the French Society for Pediatric Oncology. Children were recruited during a routine consultation. Most of them had completed treatment. The version of the questionnaire for French adults was adapted linguistically for children. Open-ended queries by children about the comprehensiveness of the questions and very low non-response rates showed a good acceptability of the questionnaire. The main psychometric properties of the HUI 2 and HUI 3 classification systems were assessed in 3 groups of raters (child, parent, physician): construct validity was tested against the rating of the child's health state on a Likert scale and through comparison with clinical data, and internal consistency was determined through multi-trait analysis. Weighted and unweighted kappa values were used to measure the inter-rater agreement between the child's, parent's and physician's assessment of the child's health state. The convergent validity was satisfactory, with better results when the physician's assessment was used. The most affected attributes were the expected ones (i.e. cognition, pain and emotion). Disagreement was observed between the 3 raters, more often in the same direction: taking the child's assessment as the reference, the parents tended to under-estimate the health status while physicians tended to over-estimate it., Journal Article, Multicenter Study, info:eu-repo/semantics/published
- Published
- 1999
22. Treatment of high risk medulloblastomas in children above the age of 3 years: A SFOP study
- Author
-
Verlooy, J., primary, Mosseri, V., additional, Bracard, S., additional, Tubiana, A. Lellouch, additional, Kalifa, C., additional, Pichon, F., additional, Frappaz, D., additional, Chastagner, P., additional, Pagnier, A., additional, Bertozzi, A.-I., additional, Gentet, J.C., additional, Sariban, E., additional, Rialland, X., additional, Edan, C., additional, Bours, D., additional, Zerah, M., additional, Le Gales, C., additional, Alapetite, C., additional, and Doz, F., additional
- Published
- 2006
- Full Text
- View/download PDF
23. CO-01-à CO-17 Mercredi 8 mars 2006 (10 h 00-12 h 30)
- Author
-
Carsin Nicol, B., primary, Ferre, J.C., additional, Bruneau, B., additional, Riffaud, L., additional, Edan, C., additional, and Treguier, C., additional
- Published
- 2006
- Full Text
- View/download PDF
24. Fistulisation d’adénopathies médiastinales dans les bronches en rapport avec une maladie de Hodgkin
- Author
-
Brinchault, G., primary, Rochefort-Morel, C., additional, Morel, V., additional, Edan, C., additional, Caulet-Maugendre, S., additional, Lena, H., additional, and Delaval, Ph., additional
- Published
- 2004
- Full Text
- View/download PDF
25. Prognostic Factors in Children With Localized Malignant Nonseminomatous Germ Cell Tumors
- Author
-
Baranzelli, M. C., primary, Kramar, A., additional, Bouffet, E., additional, Quintana, E., additional, Rubie, H., additional, Edan, C., additional, and Patte, C., additional
- Published
- 1999
- Full Text
- View/download PDF
26. 185 French adaptation of the health utilities index (HUI): A health-related quality of life instrument, in children with brain cancer
- Author
-
Le Gales, C., primary, Costet, N., additional, Gentet, J.C., additional, Kalifa, C., additional, Frappaz, D., additional, Edan, C., additional, Sariban, E., additional, Plantaz, D., additional, and Doz, F., additional
- Published
- 1999
- Full Text
- View/download PDF
27. Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: A multicenter study.
- Author
-
Dufour C, Beaugrand A, Le Deley MC, Bourdeaut F, André N, Leblond P, Bertozzi AI, Frappaz D, Rialland X, Fouyssac F, Edan C, Grill J, Quidot M, and Varlet P
- Published
- 2012
- Full Text
- View/download PDF
28. Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience.
- Author
-
Bouffet, E, Baranzelli, M C, Patte, C, Portas, M, Edan, C, Chastagner, P, Mechinaud-Lacroix, F, and Kalifa, C
- Subjects
TUMORS ,GERM cells - Abstract
Conventional therapy for intracranial germinomas is craniospinal irradiation. In 1990, the Société Française d'Oncologie Pédiatrique initiated a study combining chemotherapy (alternating courses of etoposide-carboplatin and etoposide-ifosfamide for a recommended total of four courses) with 40 Gy local irradiation for patients with localized germinomas. Metastatic patients were allocated to receive low-dose craniospinal radiotherapy. Fifty-seven patients were enrolled between 1990 and 1996. Forty-seven had biopsy-proven germinoma. Biopsy was not performed in ten patients (four had diagnostic tumour markers and in six the neurosurgeon felt biopsy was contraindicated). Fifty-one patients had localized disease, and six leptomeningeal dissemination. Seven patients had bifocal tumour. All but one patient received at least four courses of chemotherapy. Toxicity was mainly haematological. Patients with diabetus insipidus (n = 25) commonly developed electrolyte disturbances during chemotherapy. No patient developed tumour progression during chemotherapy. Fifty patients received local radiotherapy with a median dose of 40 Gy to the initial tumour volume. Six metastatic patients, and one patient with localized disease who stopped chemotherapy due to severe toxicity, received craniospinal radiotherapy. The median follow-up for the group was 42 months. Four patients relapsed 9, 10, 38 and 57 months after diagnosis. Three achieved second complete remission following salvage treatment with chemotherapy alone or chemo-radiotherapy. The estimated 3-year survival probability is 98% (CI: 86.6-99.7%) and the estimated 3-year event-free survival is 96.4% (CI: 86.2-99.1%). This study shows that excellent survival rates can be achieved by combining chemotherapy and local radiotherapy in patients with non-metastatic intracranial germinomas. [ABSTRACT FROM AUTHOR]
- Published
- 1999
29. A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency.
- Author
-
Coignard-Biehler H, Mahlaoui N, Pilmis B, Barlogis V, Brosselin P, De Vergnes N, Debré M, Malphettes M, Frange P, Catherinot E, Pellier I, Durieu I, Perlat A, Royer B, Le Quellec A, Jeziorski E, Fischer A, Lortholary O, Aaron L, Adoue D, Aguilar C, Aladjidi N, Alcais A, Amoura Z, Arlet P, Armari-Alla C, Bader-Meunier B, Bayart S, Bertrand Y, Bienvenu B, Blanche S, Bodet D, Bonnotte B, Borie R, Boutard P, Briandet C, Brion JP, Brouard J, Cohen-Beaussant S, Costes L, Couderc LJ, Cougoul P, Courteille V, de Saint Basile G, Devoldere C, Deville A, Donadieu J, Dore E, Dulieu F, Edan C, Entz-Werle N, Fieschi C, Forestier A, Fouyssac F, Gajdos V, Galicier L, Gandemer V, Gardembas M, Gaud C, Guillerm G, Hachulla E, Hamidou M, Hermine O, Hoarau C, Humbert S, Jaccard A, Jacquot S, Jais JP, Jaussaud R, Jeandel PY, Kebaili K, Korganow AS, Lambotte O, Lanternier F, Larroche C, Lascaux AS, Le Moigne E, Le Moing V, Lebranchu Y, Lecuit M, Lefevre G, Lemal R, Te VLT, Marie-Cardine A, Silva NM, Masseau A, Massot C, Mazingue F, Merlin E, Michel G, Millot F, Monlibert B, Monpoux F, Moshous D, Mouthon L, Munzer M, Neven B, Nove-Josserand R, Oksenhendler E, Ouachée-Chardin M, Oudot C, Pagnier A, Pasquali JL, Pasquet M, Perel Y, Picard C, Piguet C, Plantaz D, Provot J, Quartier P, Rieux-Laucat F, Roblot P, Roger PM, Rohrlich PS, Rubie H, Salle V, Sarrot-Reynauld F, Servettaz A, Stephan JL, Schleinitz N, Suarez F, Swiader L, Taque S, Thomas C, Tournilhac O, Thumerelle C, Tron F, Vannier JP, and Viallard JF
- Subjects
- Adult, Child, Communicable Disease Control, Communicable Diseases etiology, Disease Management, France epidemiology, Humans, Incidence, Pre-Exposure Prophylaxis, Primary Immunodeficiency Diseases diagnosis, Primary Immunodeficiency Diseases etiology, Primary Immunodeficiency Diseases therapy, Public Health Surveillance, Treatment Outcome, Emergency Medical Services, Hospitalization, Primary Immunodeficiency Diseases epidemiology
- Abstract
Purpose: Patients with primary immunodeficiency (PID) are at risk of serious complications. However, data on the incidence and causes of emergency hospital admissions are scarce. The primary objective of the present study was to describe emergency hospital admissions among patients with PID, with a view to identifying "at-risk" patient profiles., Methods: We performed a prospective observational 12-month multicenter study in France via the CEREDIH network of regional PID reference centers from November 2010 to October 2011. All patients with PIDs requiring emergency hospital admission were included., Results: A total of 200 admissions concerned 137 patients (73 adults and 64 children, 53% of whom had antibody deficiencies). Thirty admissions were reported for 16 hematopoietic stem cell transplantation recipients. When considering the 170 admissions of non-transplant patients, 149 (85%) were related to acute infections (respiratory tract infections and gastrointestinal tract infections in 72 (36%) and 34 (17%) of cases, respectively). Seventy-seven percent of the admissions occurred during winter or spring (December to May). The in-hospital mortality rate was 8.8% (12 patients); death was related to a severe infection in 11 cases (8%) and Epstein-Barr virus-induced lymphoma in 1 case. Patients with a central venous catheter (n = 19, 13.9%) were significantly more hospitalized for an infection (94.7%) than for a non-infectious reason (5.3%) (p = 0.04)., Conclusion: Our data showed that the annual incidence of emergency hospital admission among patients with PID is 3.4%. The leading cause of emergency hospital admission was an acute infection, and having a central venous catheter was associated with a significantly greater risk of admission for an infectious episode.
- Published
- 2019
- Full Text
- View/download PDF
30. Involvement of germline DDX1-MYCN duplication in inherited nephroblastoma.
- Author
-
Fievet A, Belaud-Rotureau MA, Dugay F, Abadie C, Henry C, Taque S, Andrieux J, Guyetant S, Robert M, Dubourg C, Edan C, Rioux-Leclercq N, Odent S, and Jaillard S
- Subjects
- Adult, Carcinogenesis genetics, Child, Preschool, Chromosomes, Human, Pair 8 genetics, Comparative Genomic Hybridization, Female, Genetic Predisposition to Disease, Humans, Kidney Neoplasms diagnosis, Male, N-Myc Proto-Oncogene Protein, Pedigree, Wilms Tumor diagnosis, DEAD-box RNA Helicases genetics, Gene Duplication, Germ-Line Mutation, Kidney Neoplasms genetics, Nuclear Proteins genetics, Oncogene Proteins genetics, Wilms Tumor genetics
- Abstract
This report concerns a 3-year-old girl with prenatal bilateral nephroblastomatosis and a family history of nephroblastoma. This girl had a chromosome 8 pericentric inversion inherited from her father. This inversion was observed in healthy individuals of the family and was absent in other individuals suffering from embryonic kidney tumor. We then supposed that another genetic anomaly predisposed her to tumorogenesis. Additional cryptic imbalances are reported in cases of apparently balanced chromosomal rearrangements with an abnormal phenotype. Array-CGH analysis showed a 569 kb duplication at 2p24.3 including the DDX1 and MYCN genes. This duplication was inherited from the patient's father who also had a nephroblastoma. A link between germline MYCN duplication and the occurrence of other embryonic cancers such as neuroblastoma has already been described. We supposed that germline DDX1-MYCN duplication could also be involved in the apparition of nephroblastomas., (Copyright © 2013 Elsevier Masson SAS. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
31. Primary gliomatosis cerebri involving gray matter in pediatrics: a distinct entity? A multicenter study of 14 cases.
- Author
-
Chappé C, Riffaud L, Tréguier C, Carsin-Nicol B, Veillard D, Chiforeanu DC, Grill J, Frappaz D, André N, Millot F, Vinchon M, Sirvent N, and Edan C
- Subjects
- Adolescent, Brain Neoplasms classification, Child, Child, Preschool, Female, Humans, Magnetic Resonance Imaging, Male, Neoplasms, Neuroepithelial classification, Prognosis, Retrospective Studies, Brain Neoplasms pathology, Cerebral Cortex pathology, Neoplasms, Neuroepithelial pathology, Nerve Fibers, Unmyelinated pathology
- Abstract
Background and Purpose: Gliomatosis cerebri (GC) is a rare neoplasm including a variety of tumors, with extremely variable evolution and heterogeneity of prognosis. It may appear either de novo or after a focal glioma, involve predominantly the white or the gray matter, and concern either pediatric or adult patients. We focused on primary GC involving exclusively gray matter in a pediatric population in order better to define the presentation and outcome of this disease., Patients and Methods: We reviewed the databases of seven Departments of Pediatric Oncology to identify pediatric cases of GC between 1990 and 2007. Patients were included if they demonstrated a diffuse infiltrative process involving gray matter in magnetic resonance imaging (MRI) and histological tissue analyses, confirming a proliferative glial disorder., Results: Fourteen patients with a median age of 8 years were identified. Epilepsy was the main presenting symptom. Brain MRI showed a lesion of the temporal and insular cerebral cortex associated with tumoral infiltration of the thalami and the basal ganglia. Histological examination confirmed the diagnosis of high-grade glioma. Prognosis was always very gloomy in the short term, with a median survival of less than a year., Conclusion: This rare entity, whose prognosis is appalling whatever the treatment proposed, should be clearly identified within the heterogeneous group of GC in the same way as diffuse intrinsic pontine gliomas have been identified among brain stem tumors. Systematic biopsies appear essential to permit the molecular studies which will assist in guiding the choice of future targeted treatments.
- Published
- 2013
- Full Text
- View/download PDF
32. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE).
- Author
-
Gorde-Grosjean S, Oberlin O, Leblanc T, Pacquement H, Donadieu J, Lambilliotte A, Schell M, Dommange F, Munzer M, Paillard C, Schmitt C, Lutz P, Edan C, Ansoborlo S, Stephan JL, Michel G, Thomas C, Perel Y, Robert A, and Landman-Parker J
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Child, Child, Preschool, Combined Modality Therapy mortality, Disease Progression, Disease-Free Survival, Female, France epidemiology, Hodgkin Disease mortality, Humans, Male, Retrospective Studies, Salvage Therapy mortality, Stem Cell Transplantation mortality, Treatment Outcome, Hodgkin Disease therapy, Neoplasm Recurrence, Local mortality
- Abstract
There is little data available regarding children and adolescents with Hodgkin lymphoma (HL) who relapse after combined-modality treatment, even though they have a substantial chance of cure. The purpose of this national retrospective study was to evaluate the outcome of patients with recurrent/refractory HL and determine adverse prognostic factors. From 1990 to 2006, 70 patients (median age 13·9 years) with refractory (n = 31) or first relapse (n = 39) HL were identified. Median time from end of treatment to relapse was 6 months (3-56). Relapses occurred in irradiated areas in 43/70 patients. Salvage therapy consisted of chemotherapy and 50 patients received high-dose chemotherapy with autologous stem cell transplantation. Radiotherapy was performed in 29 cases, tandem autologous transplantation in five and allograft in three. With a median follow-up of 40 months (2-140), significant prognostic factors were time to progression/relapse and response to therapy before autograft. Event-free survival and overall survival in patients with refractory disease, early relapse and late relapse were 35 ± 9%, 67 ± 11%, 76 ± 10% and 48 ± 11%, 89 ± 7% and 80 ± 10%, respectively. As progression <3 months was a major adverse prognostic factor, novel therapeutic approaches are needed for this group of patients. By contrast, patients have substantial chance of long term second remission in case of relapse >3 months., (© 2012 Blackwell Publishing Ltd.)
- Published
- 2012
- Full Text
- View/download PDF
33. SMARCB1 deficiency in tumors from the peripheral nervous system: a link between schwannomas and rhabdoid tumors?
- Author
-
Rizzo D, Fréneaux P, Brisse H, Louvrier C, Lequin D, Nicolas A, Ranchère D, Verkarre V, Jouvet A, Dufour C, Edan C, Stéphan JL, Orbach D, Sarnacki S, Pierron G, Parfait B, Peuchmaur M, Delattre O, and Bourdeaut F
- Subjects
- Biomarkers, Tumor analysis, Child, Child, Preschool, Chromosomal Proteins, Non-Histone analysis, DNA-Binding Proteins analysis, Female, Gene Deletion, Genes, Neurofibromatosis 2, Genetic Predisposition to Disease, Hemizygote, Humans, Immunohistochemistry, Infant, Infant, Newborn, Magnetic Resonance Imaging, Male, Middle Aged, Neurilemmoma chemistry, Neurilemmoma pathology, Paris, Peripheral Nervous System Neoplasms chemistry, Peripheral Nervous System Neoplasms pathology, Phenotype, Predictive Value of Tests, Rhabdoid Tumor chemistry, Rhabdoid Tumor pathology, SMARCB1 Protein, Sequence Analysis, DNA, Transcription Factors analysis, Biomarkers, Tumor genetics, Chromosomal Proteins, Non-Histone genetics, DNA-Binding Proteins genetics, Gene Silencing, Neurilemmoma genetics, Peripheral Nervous System Neoplasms genetics, Rhabdoid Tumor genetics, Transcription Factors genetics
- Abstract
Background: Inactivation of SMARCB1 tumor-suppressor gene was originally described as highly specific for rhabdoid tumors (RTs). Nevertheless, recent reports have illustrated that SMARCB1 alterations also characterize other tumors; in particular, some familial schwannomatosis and epithelioid malignant peripheral nerve sheath tumors, both from peripheral nervous system (PNS) origin, lack BAF47 expression. To document the putative role of SMARCB1 in PNS, we reviewed PNS tumors referred to our institution for a molecular analysis of SMARCB1 because of histologic features compatible with RT., Methods: Clinicopathologic, radiologic, and molecular characteristics were detailed for the 12 cases showing loss of expression and/or biallelic inactivation of SMARCB1. The status of the NF2 gene, likely to synergize with SMARCB1 in PNS tumors, was also analyzed., Results: Patients' age ranged from 0 to 45 years (median age, 6.6 y). Neurological symptoms were observed in 7/12 cases with radiologic features evoking a neuroblastic tumor in 6 cases and a peripheral nerve tumor in 4 cases. The mean delay before diagnosis was 3 months. Histologic examination revealed rhabdoid features in 11/12 tumors. All tumors showed a complete loss of SMARCB1 expression. Interestingly, adjacent nervous proliferation resembling neurofibromas were observed in 3 cases, suggesting a multistep transformation. Three tumors harbored a hemizygous deletion at the NF2 locus, but all NF2 sequences were normal., Conclusions: We report the first series of PNS RT. In patients with aggressive PNS tumors, RT should be suspected, and anti-SMARCB1 immunohistochemical analysis should be performed. SMARCB1 inactivation, occasionally associated with NF2 deletion, might have oncogenic effects in peripheral nerves.
- Published
- 2012
- Full Text
- View/download PDF
34. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.
- Author
-
Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, Mazingue F, Lutz P, Vérité C, Berthou C, Galambrun C, Bernard F, Yacouben K, Bordigoni P, Edan C, Reguerre Y, Couillault G, Méchinaud F, Cayuela JM, and Guilhot F
- Subjects
- Adolescent, Antineoplastic Agents adverse effects, Antineoplastic Agents pharmacology, Benzamides, Child, Child, Preschool, Disease-Free Survival, Dose-Response Relationship, Drug, Drug-Related Side Effects and Adverse Reactions, France, Humans, Imatinib Mesylate, Infant, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Piperazines adverse effects, Piperazines pharmacology, Prospective Studies, Pyrimidines adverse effects, Pyrimidines pharmacology, Survival Analysis, Antineoplastic Agents therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Piperazines therapeutic use, Pyrimidines therapeutic use
- Abstract
Purpose: Imatinib is the standard of care in adults with chronic myeloid leukemia (CML) in chronic phase (CP). Only a few studies to assess efficacy in children have been performed. We report on the results of the French prospective trial (ClinicalTrials.gov identifier NCT00845221) conducted in children and adolescents with newly diagnosed CML in CP., Patients and Methods: A total of 44 patients from age 10 months to 17 years with newly diagnosed CML in CP received daily imatinib 260 mg/m(2). Progression-free survival, responses, and tolerance were evaluated., Results: With a median follow-up times of 31 months (range, 11 to 64 months), the estimated progression-free survival rate at 36 months was 98% (95% CI, 85% to 100%). A complete hematologic response was achieved in 98% of the patients. The rates of complete cytogenetic response (CCyR) and major molecular response (MMR) were 61% and 31% at 12 months, respectively. During follow-up, CCyR and MMR were achieved in 36 children (77%) and 25 children (57%), respectively. Overall, 30% of the patients discontinued imatinib, mainly because of unsatisfactory response. The most common adverse events were neutropenia and musculoskeletal events., Conclusion: Imatinib is effective in children with CML in CP with response rates similar to rates reported in adults. The adverse effects are acceptable, but longer follow-up studies are required to fully assess the long-term impact.
- Published
- 2011
- Full Text
- View/download PDF
35. [Hodgkin disease and autoimmunity in children: 11 case reports].
- Author
-
Jarrassé C, Pagnier A, Edan C, Landman-Parker J, Mazingue F, Mansuy L, Bertrand Y, Paillard C, Pellier I, Margueritte G, and Plantaz D
- Subjects
- Adolescent, Autoimmune Diseases epidemiology, Child, Child, Preschool, Female, Humans, Male, Retrospective Studies, Autoimmune Diseases complications, Autoimmunity, Hodgkin Disease complications, Hodgkin Disease immunology
- Abstract
The association of lymphoma and autoimmune manifestations has been predominantly studied in adults affected by non-Hodgkin lymphoma. Few publications exist in the literature concerning Hodgkin lymphoma, particularly in children and adolescents. The objectives of this study were to define the characteristics of the link between Hodgkin disease and autoimmunity in childhood. The present 25-year retrospective study was conducted in all centers affiliated with the French Society of Paediatric Oncology (SFCE). Eleven children with Hodgkin disease presented manifestations of disimmunity preceding or following their diagnosis. Four patients had thrombocytopenic purpura, the remaining 7 each had a different autoimmune pathology: lupus syndrome, antiphospholipid syndrome with transient ischemic attack, Evans syndrome, leukocytoclastic vasculitis, autoimmune hemolytic anemia, autoimmune thyroiditis, and juvenile idiopathic arthritis. Lymphoma relapse occurred in 3 patients. Two children died, death being directly attributed to the autoimmune disease in 1 case. Our data suggest that development of autoimmunity is related to significant morbidity. Possible pathophysiological mechanisms include lymphocyte proliferation secondary to chronic inflammation, cell-mediated immune deficiency in Hodgkin disease, molecular mimetics, and antineoplastic phenomena are discussed. A study with a larger patient population is needed to identify the group of children at high risk of autoimmunity for whom additional investigations and modified therapy may be indicated., (Copyright © 2011 Elsevier Masson SAS. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
36. School performance of childhood cancer survivors: mind the teenagers!
- Author
-
Bonneau J, Lebreton J, Taque S, Chappe C, Bayart S, Edan C, and Gandemer V
- Subjects
- Adolescent, Child, Child, Preschool, Female, Humans, Infant, Male, Risk Factors, Survivors, Educational Status, Neoplasms
- Abstract
Objective: To assess school performance in an unselected group of childhood cancer survivors and study risk factors for impairment., Study Design: Rates of repeating a grade were compared for patients with cancer, their siblings, and the general population. Phone questionnaires were administered to patients about the school career of their child in remission and their siblings. Responses about cancer survivors were compared with those concerning their siblings and various registries provided by the national board of education. The primary outcome was the rate of repeating a grade., Results: A total of 148 children in remission with a mean age of 15 ± 5.3 years and a mean follow-up period since diagnosis of 6.3 ± 1.3 years were included. More patients than siblings repeated a grade (33% versus 21%; P = .02), with a mean delay since diagnosis of 2 years. Risk factors were an older age at diagnosis, attending a secondary school, low education level of parents, bone marrow transplantation, cerebral surgery, and physical sequelae. In multivariate analysis, risk for repeating was associated with low educational level of the father, attending secondary school at diagnosis, and requiring school-organized educational support on return to school., Conclusion: After cancer, repeating a grade is not an exceptional occurrence, especially for teenagers; follow-up and supportive interventions before returning to school would be beneficial., (Copyright © 2011 Mosby, Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
37. Late ovarian relapse of TEL/AML1 positive ALL confirming that TEL deletion is a secondary event in leukemogenesis.
- Author
-
Ly-Sunnaram B, Henry C, Gandemer V, Mee FL, Burtin F, Blayau M, Cayuela JM, Oster M, Clech P, Rambeau M, Marie C, Pampin C, Edan C, Gall EL, and Goasguen JE
- Subjects
- Adolescent, Core Binding Factor Alpha 2 Subunit, Female, Humans, Immunophenotyping, In Situ Hybridization, Fluorescence, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Recurrence, Reverse Transcriptase Polymerase Chain Reaction, Gene Deletion, Oncogene Proteins, Fusion genetics, Ovarian Neoplasms secondary, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology
- Abstract
We describe here a late extramedullary ovarian relapse in an 18-year-old female who was diagnosed with hypotetraploid cell acute lymphoblastic leukaemia (cALL) at the age of 6. At both occurrences of the disease cells were analyzed by morphology, immunophenotyping, cytogenetics and molecular methods. TEL/AML1 was detected by RT-PCR and FISH analysis in both events. We demonstrated, using detection of IGH/TCR rearrangements and TEL/AML1 breakpoints sequencing that the cells were clonally related. Moreover, interphasic FISH using TEL and AML1 probes showed the loss of a second TEL at the time of relapse. This observation confirms that TEL/AML1 alone is not sufficient to trigger ALL and that TEL deletion is a secondary event in leukemogenesis. To our knowledge, it is the first complete description of extramedullary ALL relapse combining all methodologies.
- Published
- 2005
- Full Text
- View/download PDF
38. Impact of Topoisomerase II alpha and spermine on the clinical outcome of children with acute lymphoblastic leukemia.
- Author
-
Grandgirard N, Ly-Sunnaram B, Ferrant D, Gandemer V, Edan C, Le Gall E, Moulinoux JP, Leray E, and Goasguen JE
- Subjects
- Antigens, Neoplasm, Child, Cytoplasm chemistry, DNA-Binding Proteins, Disease-Free Survival, Drug Resistance, Neoplasm, Humans, Immunohistochemistry, Precursor Cell Lymphoblastic Leukemia-Lymphoma metabolism, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Prognosis, Retrospective Studies, DNA Topoisomerases, Type II analysis, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Spermine analysis
- Abstract
It has been reported in the literature that a leukemic cell may be (or become) resistant to anti-cancer treatment because many mechanisms, such as efflux membrane pump (multi-drug resistance, MDR-P170), intracellular transport (LRP, MRP), or different detoxification systems (glutathione transferases, methallothioneines) may be implicated. Topoisomerase II alpha (TopoII) are also reported as responsible for resistance since their main action is to repair DNA breakage. Polyamines are described as having a protective DNA action by stabilizing the double stranded DNA helix. For these reasons we investigated 65 children with acute lymphoblastic leukemia using an immunocytochemical method to elucidate the potential role of Topoisomerase and polyamines in drug resistance. Most children (60/65) were treated with the French (acute lymphoblastic leukemia, ALL) protocol (FRALLE-93) in which B and C arms include (at least) VP16. Children with cytoplasmic TopoII positivity (18 cases) were more resistant since their overall survival was 34 months compared to more than 110 months for negative cases ( P = 0.0003). Polyamines may be associated with drug resistance since the overall survivals were 51 months and 92 months for positive and negative patients, respectively, but the P-value is only 0.13. We conclude that Topoisomerase and polyamines must be tested at diagnosis as new possible markers for chemo-resistance. Larger series are needed to confirm these preliminary results and to verify if the use of anti epipodophillotoxin agents (as it is the case for FRALLE B or C) should be excluded for positive cases.
- Published
- 2004
- Full Text
- View/download PDF
39. [Bronchial erosion of mediastinal lymphadenopathy associates with Hodgkin's disease].
- Author
-
Brinchault G, Rochefort-Morel C, Morel V, Edan C, Caulet-Maugendre S, Lena H, and Delaval P
- Subjects
- Adolescent, Aged, Female, Humans, Male, Bronchial Fistula etiology, Fistula etiology, Hodgkin Disease complications, Lymphatic Diseases etiology, Mediastinal Diseases etiology
- Abstract
Introduction: Erosion of mediastinal adenopathy into the bronchial tree is classically associated with tuberculosis. We describe two cases of of such bronchial erosion with Hodgkin's disease., Case Report: The first case was of a seventy-year old man with a history of pulmonary silicosis. A sub-carenal mass was identified during investigation of chronic cough. The bronchoscopy revealed an inflammatory stenosis due to Hodgkin's disease. The second case was of a thirteen-year old child whose Hodgkin's disease was thought to be in remission following treatment. The erosion of mediastinal adenopathy into the main left bronchus produced complete left pulmonary atalectasis, which required endobronchial stenting., Conclusions: In both cases, rigid bronchoscopy provided a histological diagnosis with diagnosis of Hodgkin's disease in the first case, and identification of recurrence in the other one. These cases are unusual. Such complications are usually complications of radiotherapy. Classically, erosion of mediastinal adenopathy into the bronchial tree is tuberculous in origin but they can be neoplasic.
- Published
- 2004
- Full Text
- View/download PDF
40. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology.
- Author
-
Grill J, Le Deley MC, Gambarelli D, Raquin MA, Couanet D, Pierre-Kahn A, Habrand JL, Doz F, Frappaz D, Gentet JC, Edan C, Chastagner P, and Kalifa C
- Subjects
- Brain Neoplasms surgery, Carboplatin administration & dosage, Chemotherapy, Adjuvant, Child, Preschool, Cisplatin administration & dosage, Cyclophosphamide administration & dosage, Disease-Free Survival, Ependymoma surgery, Etoposide administration & dosage, Female, Humans, Infant, Male, Neoplasm Recurrence, Local, Procarbazine administration & dosage, Prognosis, Treatment Outcome, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brain Neoplasms drug therapy, Ependymoma drug therapy
- Abstract
Purpose: To evaluate a strategy that avoids radiotherapy in first-line treatment in children under 5 years of age with brain or posterior fossa ependymoma, by exclusively administering 16 months of adjuvant multiagent chemotherapy after surgery., Patients and Methods: Between June 1990 and October 1998, 73 children with ependymoma (82% with high-grade tumors) were enrolled onto this multicenter trial. Children received adjuvant conventional chemotherapy after surgery consisting of seven cycles of three courses alternating two drugs at each course (procarbazine and carboplatin, etoposide and cisplatin, vincristine and cyclophosphamide) over a year and a half. Systematic irradiation was not envisaged at the end of chemotherapy. In the event of relapse or progression, salvage treatment consisted of a second surgical procedure followed by local irradiation with or without second-line chemotherapy., Results: Conventional chemotherapy was well tolerated and could be administered in outpatient clinics. No radiologically documented response to chemotherapy more than 50% was observed. With a median follow-up of 4.7 years (range, 5 months to 8 years), the 4-year progression-free survival rate in this series was 22% (95% confidence interval [CI], 13% to 43%) and the overall survival rate was 59% (95% CI, 47% to 71%). Overall, 40% (95% CI, 29% to 51%) of the patients were alive having never received radiotherapy 2 years after the initiation of chemotherapy and 23% (95% CI, 14% to 35%) were still alive at 4 years without recourse to this modality. In the multivariate analysis, the two factors associated with a favorable outcome were a supratentorial tumor location (P =.0004) and complete surgery (P =.0009). Overall survival at 4 years was 74% (95% CI, 59% to 86%) for the patients in whom resection was radiologically complete and 35% (95% CI, 18% to 56%) for the patients with incomplete resection., Conclusion: A significant proportion of children with ependymoma can avoid radiotherapy with prolonged adjuvant chemotherapy. Deferring irradiation at the time of relapse did not compromise overall survival of the entire patient population.
- Published
- 2001
- Full Text
- View/download PDF
41. [Expanding mature pineal teratoma syndrome. Case report].
- Author
-
Hanna A, Edan C, Heresbach N, Ben Hassel M, and Guegan Y
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor analysis, Cerebrospinal Fluid Shunts, Chorionic Gonadotropin blood, Chorionic Gonadotropin cerebrospinal fluid, Chorionic Gonadotropin metabolism, Combined Modality Therapy, Diagnosis, Differential, Diplopia etiology, Etoposide administration & dosage, Germinoma diagnosis, Humans, Ifosfamide administration & dosage, Intracranial Hypertension etiology, Magnetic Resonance Imaging, Male, Neoplasm Invasiveness, Neoplasm Proteins blood, Neoplasm Proteins cerebrospinal fluid, Neoplasm Proteins metabolism, Pinealoma complications, Pinealoma diagnosis, Pinealoma metabolism, Pinealoma therapy, Radiotherapy, Adjuvant, Remission Induction, Teratoma complications, Teratoma diagnosis, Teratoma metabolism, Teratoma therapy, Thalamus pathology, Pinealoma pathology, Teratoma pathology
- Abstract
We present a case of growing teratoma syndrome of the pineal region. To our knowledge, this is the fourth case reported in the literature. A 13-year-old boy was referred for intracranial hypertension and bilateral papillary edema. CT scan showed a pineal region tumor with obstructive hydrocephalus. After CSF (cerebrospinal fluid) shunting, MRI showed that the tumor had a heterogenous signal enhancement. The tumor marker HCG (human chorionic gonadotrophin) was elevated in CSF and serum. After three cycles of chemotherapy, MRI showed an important increase in tumor size with morphologic modifications. However, HCG in CSF and serum returned to normal. Surgical resection was performed and histological examination of the whole specimen showed mature teratoma. On postoperative MRI, there was a small area of signal enhancement of the left thalamus. Radiotherapy was given. The child was in complete remission 15 months after the diagnosis. Growing teratoma syndrome is a mixed germ cell tumor with a secreting portion that responds to chemotherapy and a non secreting portion of mature teratoma that continues to grow under chemotherapy. The treatment should include chemotherapy for the malignant secreting portion and surgery for the mature teratoma.
- Published
- 2000
42. Primary retropharyngeal neuroblastoma.
- Author
-
Godey B, Pagot C, Morandi X, Edan C, Bourdiniere J, and Le Gall F
- Subjects
- Head and Neck Neoplasms pathology, Humans, Infant, Male, Neuroblastoma pathology, Head and Neck Neoplasms surgery, Neuroblastoma surgery
- Published
- 2000
- Full Text
- View/download PDF
43. Cross-cultural adaptation of a health status classification system in children with cancer. First results of the French adaptation of the Health Utilities Index Marks 2 and 3.
- Author
-
Le Galès C, Costet N, Gentet JC, Kalifa C, Frappaz D, Edan C, Sariban E, Plantaz D, and Doz F
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Cranial Irradiation, Cross-Cultural Comparison, France, Humans, Surveys and Questionnaires, Health Status, Neoplasms psychology, Quality of Life
- Abstract
Our objective was to adapt and validate the Health Utilities Index Mark 2 (HUI 2) and HUI 3 health status classification systems self-report questionnaire in a population of children with cancer, a group of 42 children already included in a multi-centre database designed by the Group on Brain Tumors in Children of the French Society for Pediatric Oncology. Children were recruited during a routine consultation. Most of them had completed treatment. The version of the questionnaire for French adults was adapted linguistically for children. Open-ended queries by children about the comprehensiveness of the questions and very low non-response rates showed a good acceptability of the questionnaire. The main psychometric properties of the HUI 2 and HUI 3 classification systems were assessed in 3 groups of raters (child, parent, physician): construct validity was tested against the rating of the child's health state on a Likert scale and through comparison with clinical data, and internal consistency was determined through multi-trait analysis. Weighted and unweighted kappa values were used to measure the inter-rater agreement between the child's, parent's and physician's assessment of the child's health state. The convergent validity was satisfactory, with better results when the physician's assessment was used. The most affected attributes were the expected ones (i.e., cognition, pain and emotion). Disagreement was observed between the 3 raters, more often in the same direction: taking the child's assessment as the reference, the parents tended to under-estimate the health status while physicians tended to over-estimate it., (Copyright 1999 Wiley-Liss, Inc.)
- Published
- 1999
44. [Malignant melanoma in a 7-year-old child. A report of a dramatic case].
- Author
-
Miard F, Watier E, Pailheret JP, Edan C, and Manise O
- Subjects
- Child, Fatal Outcome, Female, Humans, Melanoma congenital, Neoplasm Invasiveness, Neoplasms, Second Primary diagnosis, Nevus congenital, Scalp surgery, Skin Neoplasms congenital, Skull Neoplasms diagnosis, Melanoma surgery, Nevus surgery, Skin Neoplasms surgery
- Abstract
Malignant melanoma developed on the scalp at the site of a congenital nevus in a 7-year-old girl. At birth, simple observation was proposed, despite the recognized desirable but non-urgent indication for excision, in order to avoid subjecting the infant to general anesthesia. At the first sign of a change in the macroscopic appearance of the nevus, surgical resection was performed, but the short-term outcome was fatal.... This case focuses our attention on malignant progression of even small congenital nevi and emphasizes the need for early preventive and systematic resection even when the patient's age of the patient requires general anesthesia.
- Published
- 1997
45. [Langerhans cell granulomatosis of the orbit. Apropos of an anatomo-clinical case].
- Author
-
Toulemont PJ, Jouan H, Legall F, Edan C, and Urvoy M
- Subjects
- Child, Histiocytosis, Langerhans-Cell diagnosis, Histiocytosis, Langerhans-Cell surgery, Humans, Male, Orbital Diseases diagnosis, Orbital Diseases surgery, Histiocytosis, Langerhans-Cell pathology, Orbital Diseases pathology
- Abstract
Langerhans' cell granulomatosis of the orbit was observed in a 7-year-old boy successfully treated by a simple biopsy. Recovery can be established one year after the biopsy on the basis of bone defect healing on the standard X-ray of the skull.
- Published
- 1995
46. [Orbital rhabdomyosarcoma in children. Apropos of 2 cases].
- Author
-
Le Gall F, Edan C, Toulemont PJ, Jouan H, Urvoy M, and Ramee MP
- Subjects
- Adolescent, Child, Female, Humans, Male, Orbital Neoplasms diagnosis, Orbital Neoplasms therapy, Prognosis, Rhabdomyosarcoma diagnosis, Rhabdomyosarcoma therapy, Orbital Neoplasms pathology, Rhabdomyosarcoma pathology
- Abstract
Rhabdomyosarcoma accounts for 5% of childhood malignant tumours; in 10% it occurs in the orbit where it is the most frequent malignant tumour. Rhabdomyosarcoma is a mesenchymatous tumour with striated muscular differentiation. However, this myogenous differentiation is sometimes undiscernable on standard histological examination and requires immunohistochemical and ultrastructural studies to be shown. Treatment depends on the assessment of local extension, principally based on tomodensitometry. When the tumour is limited to the orbit, survival rate may reach 100% with todays therapeutic protocols. When the orbital walls are invaded the tumour is parameningeal and recovery can only be achieved by increasing chemotherapy at the cost of long-term side effects. Hence, this tumour must be diagnosed and treated very early. The authors report two cases of rhabdomyosarcoma dealing with the two main histological forms of the tumour and with their evolutive risks.
- Published
- 1994
47. Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease.
- Author
-
Bergeron C, Le Moine P, Le Prise-Fleury E, Jouan H, Tass P, Darcel F, Chatel M, Edan C, Patte C, and Faivre J
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biopsy, Brain Neoplasms drug therapy, Brain Neoplasms radiotherapy, Carmustine administration & dosage, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Hodgkin Disease radiotherapy, Humans, Ifosfamide administration & dosage, Lymphoma, Non-Hodgkin drug therapy, Lymphoma, Non-Hodgkin radiotherapy, Male, Methotrexate administration & dosage, Neoplasms, Second Primary, Prednisone administration & dosage, Procarbazine administration & dosage, Tomography, X-Ray Computed, Vincristine administration & dosage, Brain Neoplasms diagnosis, Hodgkin Disease drug therapy, Lymphoma, Non-Hodgkin diagnosis
- Abstract
Case report of the appearance of a highly malignant cerebral non-Hodgkin's lymphoma of a diffuse large cell type, type B, occurring at the immediate onset of chemotherapy for a stage IV (mediastino-pulmonary) Hodgkin's disease (nodular sclerosis) diagnosed in a 16-year-old boy. The treatment of this cerebral lymphoma associated primary chemotherapy with high dose methotrexate, high dose aracytine, etoposide, and ifosfamide. The chemotherapy proved to be highly efficient, producing complete remission. Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non-Hodgkin's lymphoma. This treatment was followed by 36 Gy of cerebral irradiation. Thirty-six months after the discovery of the cerebral non-Hodgkin's lymphoma the patient was still disease-free and doing well.
- Published
- 1993
- Full Text
- View/download PDF
48. [Rapid diagnosis of tuberculous meningitis by polymerase chain reaction. A case in an infant].
- Author
-
Odent S, Minet J, Lelièvre R, Edan C, La Rocca MC, and Jezequel C
- Subjects
- Humans, Infant, Male, Mycobacterium tuberculosis isolation & purification, Tuberculosis, Meningeal cerebrospinal fluid, Polymerase Chain Reaction, Tuberculosis, Meningeal diagnosis
- Abstract
A fifteen-month-old child was admitted with a week history of isolated fever. On CSF (Cerebral Spinal Fluid) examination, hyperproteinorachy, hyperglycorachy and hypochlorurachy were found. The diagnosis of tuberculosis meningitis was suspected but usual tests were unable to find Mycobacterium tuberculosis in CSF, urine and sputum. Only the Polymerase Chain Reaction detected the Mycobacterium tuberculosis genome in the CSF. A specific treatment was started immediately. Apyrexia was obtained within 2 days; the outcome was favorable, without sequelae.
- Published
- 1993
49. [Orbital and muscular relapse of Burkitt's lymphoma].
- Author
-
Bergeron C, Le Berre C, Le Moine P, Chapuis M, Edan C, Jouan H, Goasguen J, Le Gall E, and Jezequel C
- Subjects
- Bone Marrow Transplantation, Child, Combined Modality Therapy, Humans, Muscular Diseases drug therapy, Muscular Diseases surgery, Orbital Neoplasms drug therapy, Orbital Neoplasms surgery, Remission Induction, Burkitt Lymphoma complications, Muscular Diseases etiology, Orbital Neoplasms etiology
- Abstract
We report the case of a child presenting with abdominal Burkitt's lymphoma in whom a relapse presented as orbital and muscle involvement. This clinical feature is extremely rare. Two muscle and one orbital biopsies were necessary to obtain proper diagnosis. A new extension check-up showed bone marrow invasion and normal cerebrospinal fluid. This relapse was successfully treated by conventional chemotherapy and consolidated with high-dose chemotherapy, total body irradiation and autologous bone marrow transplantation. Eighteen months after transplantation, the child may be considered as definitively cured.
- Published
- 1991
50. Epidemiologic survey of juvenile chronic arthritis in France. Comparison of data obtained from two different regions.
- Author
-
Prieur AM, Le Gall E, Karman F, Edan C, Lasserre O, and Goujard J
- Subjects
- Adolescent, Child, Child, Preschool, Cross-Sectional Studies, Demography, Female, Follow-Up Studies, France, Geography, Humans, Infant, Male, Retrospective Studies, Arthritis, Juvenile epidemiology
- Abstract
An epidemiologic survey of JCA was carried out in two regions of France, the western part of Paris and Brittany, differing in terms of geological background and demography. The prevalence was 0.77 and 0.100% and the incidence 0.019 and 0.013%, respectively. The type of onset, the course of the disease, the immunological data and the degree of final disability were similar in both regions. These data were compared to other studies and the factors of possible discrepancy analysed.
- Published
- 1987
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.